DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study
Key facts
- Where
- Copenhagen Nv, DániaSee the site
- Phase
- 4. fázis
Where in Dánia
- Bispebjerg HospitalCopenhagen Nv, DániaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bispebjerg Hospital
- Trial code
- EU 2022-501912-32-00
- Record updated
- 2023. július 17.
- Original description
Compared the four NOACs head-to-head in order to evaluate the safety, efficiency and whether the four NOACs are equally effective in preventing death and hospitalizations without increasing risk of major bleeding in patients with 1) atrial fibrillaiton (and atrial flutter), and 2) in patients with deep vein trombosis or/and pulmonary embolism.Read full original descriptionShow less
Compared the four NOACs head-to-head in order to evaluate the safety, efficiency and whether the four NOACs are equally effective in preventing death and hospitalizations without increasing risk of major bleeding in patients with 1) atrial fibrillaiton (and atrial flutter), and 2) in patients with deep vein trombosis or/and pulmonary embolism.
Inclusion: DANNOAC-AF: A diagnosis of atrial fibrillation (and atrial flutter) in outpatient clinic or as discharge diagnosis after hospitalization, and claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit. DANNOAC-VTE: A diagnosis of deep vein trombosis and/or pulmonary embolus in outpatient clinic or as discharge diagnosis after hospitalization. A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.
Exclusion: A prescription of a NOAC within 90 days prior to hospitalization.